Category - News

Developments

BriaCell announces clinical data at 2019 San Antonio Breast Cancer Symposium

BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXF) presented results of clinical studies with its lead product candidate, Bria-IMT, in combination with immune checkpoint inhibitors in advanced breast cancer at 2019 San...

December 13, 2019

Markets

SVB Leerink ups Wave Life Sciences PT to $46 from $40

SVB Leerink raised its price target for Wave Life Sciences (NASDAQ:WVE) to $46 from $40 after the FDA approved Sarepta Therapeutics’ (NASDAQ:SRPT) golodirsen for the treatment of Duchenne muscular dystrophy (DMD) in...

December 13, 2019

Developments

Soricimed updates peptide-drug conjugate program

Closely-held Soricimed Biopharma updated its peptide-drug conjugate (PDC) program, which enables delivery of a cytotoxic drug payload bound to a targeting peptide directly to receptors that are overexpressed by cancer...

December 12, 2019

Developments

iBio unveils FastGlycaneering Development Service to produce recombinant proteins

iBio (NYSE AMERICAN:IBIO) unveiled its FastGlycaneering Development Service, which includes an array of new glycosylation technologies for engineering high-performance recombinant proteins. Biopharmaceutical innovators...

December 11, 2019

Executive Moves

Zenabis names Kevin Coft as interim CEO

Zenabis Global (TSX:ZENA) appointed Kevin Coft as interim CEO, effective immediately, replacing Andrew Grieve, whose contract was set to expire shortly. While Mr. Grieve will be returning to his investment business, he...

December 11, 2019

Markets

Analysts downgrade Correvio Pharma as FDA Adcom rejects Brinavess

Analysts for H.C. Wainwright, Mackie Research and Echelon Wealth Partners downgraded Correvio Pharma (NASDAQ:CORV) after the FDA Cardiovascular and Renal Drugs Advisory Committee voted 11-2 against recommending approval...

December 11, 2019

Markets

Mackie Research ups Theratechnologies to buy; holds PT at $6.50

Mackie Research upgraded Theratechnologies (TSX:TH; NASDAQ:THTX) to “buy” from “hold” but maintained its price target at $6.50 (Canadian), saying the current share price represents a favorable risk-reward situation...

December 11, 2019

Developments

Hepion advances to next dosing level in ongoing Phase 1 study of CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) advanced to the next higher dose of CRV431 in its ongoing Phase 1 multiple ascending dose trial in healthy volunteers. The clinical trial management team determined the 75 mg dosing...

December 10, 2019

Developments

Tonix Pharmaceuticals enrolls first patient in Phase 3 fibromyalgia study

Tonix Pharmaceuticals (NASDAQ:TNXP) enrolled the first patient in its Phase 3 study of TNX-102 SL for the management of fibromyalgia. TNX-102 SL is a non-opioid analgesic, administered daily at bedtime. The trial will...

December 10, 2019

Developments

Dermira atopic dermatitis drug gets FDA fast track designation

Dermira’s (NASDAQ:DERM) lebrikizumab received FDA fast track designation for the treatment of moderate-to-severe atopic dermatitis. Lebrikizumab is a humanized monoclonal antibody that targets interleukin-13, which is...

December 10, 2019

Category - News

BriaCell announces clinical data at 2019 San Antonio Breast Cancer Symposium

SVB Leerink ups Wave Life Sciences PT to $46 from $40

Soricimed updates peptide-drug conjugate program

iBio unveils FastGlycaneering Development Service to produce recombinant proteins

Zenabis names Kevin Coft as interim CEO

Analysts downgrade Correvio Pharma as FDA Adcom rejects Brinavess

Mackie Research ups Theratechnologies to buy; holds PT at $6.50

Hepion advances to next dosing level in ongoing Phase 1 study of CRV431

Tonix Pharmaceuticals enrolls first patient in Phase 3 fibromyalgia study

Dermira atopic dermatitis drug gets FDA fast track designation

General

More